---
title: "Lixisenatide: Parkinson's Drug Pipeline"
description: "A repurposed diabetes drug tested to see if it slows Parkinson's. A Phase 2 trial found a small slowing of symptom worsening, alongside notable nausea."
canonical_url: "https://parkinsonspathways.com/pipeline/lixisenatide-glp1"
development_stage: "Phase 2: mid-stage testing"
last_updated: 2026-06-01
source: "Parkinson's Pathways"
---
# Lixisenatide

**Stage:** Phase 2 (LixiPark)  ·  **Type:** Disease-modifying

**Developer:** Academic / investigator-led (originally a Sanofi diabetes drug)

**How it works:** A diabetes drug (a GLP-1 agonist) being repurposed to see whether it protects brain cells in Parkinson's.

**Target:** GLP-1 receptor

**Who it's for:** People with early Parkinson's.

**Key trials:** NCT03439943

**Last reviewed:** 2026-06-01


## What it is

Lixisenatide belongs to the GLP-1 class of diabetes/weight drugs (the same broad family as semaglutide). Researchers are testing whether their effects on inflammation and cell metabolism might protect dopamine-producing brain cells.

## Where it stands

The French LixiPark Phase 2 trial has reported results. Larger confirmatory work would be needed before this could change practice.

## What the data shows so far

LixiPark enrolled about 156 people with early Parkinson's for 12 months. Those on lixisenatide had almost no worsening of their motor score over the year, while the placebo group worsened slightly, a small but statistically significant difference on the MDS-UPDRS motor scale. Nausea and vomiting were common side effects, and the long-term meaning of a small one-year difference is uncertain.

## What families should know

This is an interesting disease-modifying signal from a repurposed, well-understood drug, but it is one mid-sized study over a single year. It is not approved for Parkinson's, and the related drug exenatide failed a larger Parkinson's trial, which is a cautionary note for the whole GLP-1 approach.

## Caveats

Single Phase 2 trial; the difference, while significant, was small and measured over only one year. Frequent nausea/vomiting. A closely related GLP-1 drug (exenatide) later failed its Phase 3 Parkinson's trial, so the class is far from proven.

## Timeline

_Most recent first._

- **2024**, LixiPark Phase 2 results published (small motor benefit).

## Sources

- [LixiPark on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03439943)

_Last reviewed: 2026-06-01._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)